Johnson & Johnson (JNJ) reported second-quarter earnings that beat estimates on both revenue and profit. The enterprise posted revenue of $22.45 billion, surpassing the expected $22.34 billion, while adjusted EPS came in at $2.82, above the projected $2.71. Despite this strong performance, JNJ lowered its full-year guidance, citing impacts from recent acquisitions.
Johnson & Johnson CFO Joe Wolk joins Yahoo money health reporter Anjalee Khemlani to discuss the results.
Wolk expresses satisfaction with the enterprise’s top-line development in the second quarter, noting expansion across various enterprise segments and products. While acknowledging that its medtech segment’s sales fell slightly short of expectations, he details the enterprise’s development plans for this sector moving forward.
Wolk highlights the recent acquisition of Abiomed, describing it as “a nice complement” that strengthens JNJ’s position in the cardiovascular space. “I think we’re very well positioned to play in these higher development markets,” Wolk states, remaining optimistic about the medtech enterprise’ potential despite the quarter’s disappointing performance.
“Continuing to come up with new innovative medicines that raise the standard of care is really what is the formula for our success,” Wolk tells Yahoo financial.
#news #youtube #pharmaceutical
About Yahoo financial:
Yahoo financial provides free stock ticker data, up-to-date news, collection of investments management resources, comprehensive sector data, advanced tools, and more information to help you manage your financial life.
– Get the latest news and data at financial.yahoo.com
– Download the Yahoo financial app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)
– Follow Yahoo financial on social:
X: http://twitter.com/YahooFinance
Instagram: https://www.instagram.com/yahoofinance/?hl=en
TikTok: https://www.tiktok.com/@yahoofinance?lang=en
Facebook: https://www.facebook.com/yahoofinance/
LinkedIn: https://www.linkedin.com/enterprise/yahoo-financial
Disclaimer:
If you own the YouTube channel related to this video and do not want it to be featured here, you can contact us through our contact page. We will gladly remove it without questioning your reasons.